Podcasts about ventricular assist devices

On this episode of JHLT: The Podcast, the JHLT Digital Media Editors discuss a brand new consensus document from the ISHLT entitled “Strategies to Prevent Hemocompatibility Related Adverse Events in Patients with a Durable, Continuous-Flow Ventricular Assist Device.” The episode is hosted by Digital Media Editor Erika Lease, MD, FCCP, a transplant pulmonologist from the University of Washington.   The consensus document's lead author, Ian Hollis, PharmD, a heart failure pharmacist and Associate Professor from the University of North Carolina in Chapel Hill, joins the podcast to discuss the document.  During the discussion, he's reunited with co-author and JHLT Podcast co-host Van-Khue Ton, MD, for a lively discussion of the document's findings and takeaways.   If you work with heart failure patients with durable VADs, you'll want to listen to this episode—and check out the complete document at ISHLT.   Stay tuned for a second episode later this month, where we'll be talking about a modular simulation framework for organ allocation.

In this replay episode of 2021, week we review a work on the use of bivalirudin on outcomes of pediatric VAD patients. We speak with Dr. Caroline Carly Heyrend of Primary Children's Hospital in Utah about a recent work she co-authored on time in therapeutic range for this agent in children with VAD's. How does bivalirudin work differently than heparin and what are the theoretical benefits or disadvantages of this agent in comparison with unfractionated heparin? Why are thrombotic complications still common amongst those with pediatric VAD's even when anticoagulation is maintained appropriately? What are the factors at work that make safe anticoagulation so difficult in this complex and fragile group of patients? Dr. Heyrend provides the pharmacist's perspective this week.DOI: 10.1097/MAT.0000000000001261

The JHLT Digital Media Editors explore two manuscripts from the October issue of The Journal of Heart and Lung Transplantation—the first on lung transplantation in patients with stacked risks, and the second on bacterial pathogens found at driveline exit sites in patients with ventricular assist devices. Digital Media Editor Marty Tam, MD, assistant professor in the division of cardiovascular medicine at the University of Michigan, hosts this episode.   First, hear from senior author Edward Cantu, MD, MSCE, on his team's study “Transplanting candidates with stacked risks negatively affects outcomes.”   Lung transplant centers are increasingly evaluating patients with multiple risk factors for adverse post-transplant outcomes, yet there is little data of the effects of these risks as they stack. The authors of the study used the UNOS registry data linked to the National Inpatient Sample (NIS) to create a national encounter-level sample of healthcare data in the United States, then applied a probabilistic matching algorithm using 7 variables and determined associations between mortality, length of stay, total charges, and disposition with the number of comorbidities.   For details on what the study found about how these risks affected patient success—based on factors like mortality, length of stay, duration of mechanical ventilation, need for ECMO-salvage, total charges, and discharge to a skilled nursing facility—listen to the discussion in the episode.   Next, the editors explored the study “Dynamics of bacterial pathogens at the driveline exit site in patients with ventricular assist devices: A prospective, observational, single-center cohort study.” While the authors weren't able to join the episode, editors corresponded with senior author Monika Fürholz, MD, from the Bern University Hospital in Switzerland, before recording, and shared some of her insights.   Driveline exit site infections commonly occur in patients with LVADs, and can be a source of recurrent or deeper infections. Bacterial colonization of driveline exit sites has not been well studied, and transition from colonization to infection is also not well understood. The authors of this paper sought to address this by conducting a prospective, observational, single-center cohort study which included systematic and routine collection of driveline exit site skin swabs being taken between June 2019 and December 2021, even in the absence of suspected driveline infection. Bacteria were identified and a subset of the samples underwent whole-genome sequencing.   For details on what the study found, including a discussion of how the study findings might impact current practice, check out the episode.   Follow along at www.jhltonline.org/current, or, if you're an ISHLT member, log in at ishlt.org/journal-of-heart-lung-transplantation.  Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.    

CardioNerds (Dr. Amit Goyal), Dr. Sonu Abraham (CardioNerds Ambassador from Lahey Hospital and Medical Center, Burlington, MA) discuss left ventricular assist devices (LVAD) and the implications of renal dysfunction with Dr. Brian Houston and Dr. Nisha Bansal. This episode will focus on the intersection of left ventricular assist devices and renal dysfunction. Patients with a combination of heart failure and renal dysfunction overall have a guarded prognosis and their management poses unique challenges to the clinician. We initially discuss the basics of an LVAD and general approach to LVAD candidacy evaluation. We then discuss specific implications of acute kidney injury, presence of preexisting CKD, and end stage renal disease in patients with/being considered for an LVAD. Risk factor identification and prognostication allows for appropriate selection of the right candidates for an LVAD in the context of renal disease. Dr. Brian Houston is the Director of the Mechanical Circulatory Support program at Medical University of South Carolina. Dr. Nisha Bansal is an Associate Professor and the Arthur Stach Family Endowed Professor in the Division of Nephrology, an investigator at the Kidney Research Institute, the Director of Nephrology Clinical and Research Education, and the Director of the Kidney-Heart Service at the University of Washington. Notes were drafted by Dr. Sonu Abraham and episode audio was edited by student Dr. Chelsea Amo-Tweneboah. Check out the CardioNerds Failure Heart Success Series Page for more heart success episodes and content! CardioNerds Heart Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls - Left Ventricular Assist Devices and Renal Dysfunction End stage renal disease (CKD on dialysis) is considered an absolute contraindication for LVAD implantation. Select young patients who are being considered for heart-kidney transplantation in the near future may be candidates for an LVAD as a bridge to heart-kidney transplantation. LVAD implantation can improve kidney function in the short term in patients with AKI primarily caused by cardio-renal syndrome. Patients with pre-existing CKD (not dialysis dependent) have a greater risk of developing AKI after LVAD implantation.   Several dialysis modalities including in-center hemodialysis, home hemodialysis, and peritoneal dialysis are available for LVAD patients. However, there are several challenges associated with each modality. An AV graft is a useful vascular access option in LVAD patients undergoing hemodialysis due to a lower risk of infection and ease of immediate use. Causes for anemia in patients with an LVAD and renal dysfunction include anemia of chronic disease, gastrointestinal bleeding, and pump thrombosis leading to hemolysis. Show notes - Left Ventricular Assist Devices and Renal Dysfunction Notes: (drafted by Dr. Sonu Abraham) What is a left ventricular assist device (LVAD) and what are its components? An LVAD supports circulation by unloading the left ventricle and providing increased cardiac output to help support organ perfusion. Use in properly selected patients is associated with improved quality of life and increased survival. The current iteration of LVADs offer continuous flow, as opposed to the older versions which employed pulsatile flow. Components of the LVAD: Inflow cannula (sucks blood from the LV) Pump Outflow cannula (dumps blood into the aorta) Percutaneous driveline Electrical controller How is a patient evaluated for LVAD candidacy? The 2 main questions to be answered during the evaluation of a patient for an LVAD are:             1. Are they sick enough? Do they have end stage heart failure?             2. Do we expect the benefits of an LVAD to outweigh the risks? ...

Interview with Dr. Katsuhide Maeda MD PhD (Children's Hospital of Philadelphia) and John Dykes MD (Lucile Packard Children's Hospital) about the history and current state of VAD support for single ventricle patients. Co-Hosts: Monica Mafla MS, PNP-AC (Lucile Packard Children's Hospital/Stanford) and Amy Romer MD (Children's Hospital of Philadelphia). Editors: Monica Mafla MS, PNP-AC, and Lillian Su, MD Producer: Lillian Su, MD (Phoenix Children's Hospital)

When children suffer from heart failure and all medical options are exhausted, sometimes the next option is to use mechanical support to keep their heart going. The machine that supports this is called a Ventricular Assist Device, commonly known as a VAD. Ann & Robert H. Lurie Children's Hospital of Chicago is the home to the #1 ranked pediatric Heart Center in Illinois and offers one of the highest-volume pediatric ventricular assist device (VAD) programs in the world. We hear from the leaders of that program at Lurie Children's.

For advanced heart failure patients, treatment options may be challenging so a ventricular assist device, or VAD, might be an option to help support the heart. Dr. Meyer explains heart failure, VADS, and provides suggestions for physicians managing advanced heart failure patients or patients who might be candidates.

Ventricular Assist Devices (VAD) - Vanderbilt University Medical Center; Department of CV Surgery: Faculty Forum. Presentation by John Poland, CP, and Dr. John Hoffman.

Commentary by Dr. Valentin Fuster

This week we review a recent work on the use of bivalirudin on outcomes of pediatric VAD patients. We speak with Dr. Caroline Carly Heyrend of Primary Children's Hospital in Utah about a recent work she co-authored on time in therapeutic range for this agent in children with VAD's. How does bivalirudin work differently than heparin and what are the theoretical benefits or disadvantages of this agent in comparison with unfractionated heparin? Why are thrombotic complications still common amongst those with pediatric VAD's even when anticoagulation is maintained appropriately? What are the factors at work that make safe anticoagulation so difficult in this complex and fragile group of patients? Dr. Heyrend provides the pharmacist's perspective this week. DOI: 10.1097/MAT.0000000000001261

A ventricular assist device, also known as a VAD, is an implantable mechanical pump that helps pump blood from the lower chambers of your heart, or ventricles, to the rest of your body. Although this device can be placed in the left, right or both ventricles of your heart, it is most frequently used in the left ventricle. When placed in the left ventricle it is called a left ventricular assist device, or LVAD. A ventricular assist device is used in people who have weakened hearts or heart failure. A VAD may be implanted while the patient waits for a heart transplant or is working to get his or her heart strong enough to effectively pump blood on its own. "Patients with end-stage heart failure may be out of breath brushing their teeth or sitting in the recliner watching TV," says Dr. John Stulak, a Mayo Clinic cardiovascular surgeon. "When a patient ends up having symptoms at rest, that's the telltale sign that this is end-stage heart failure. What the LVAD does is help the left side of the heart pump and decongest the heart and get all the blood moving forward again. The VAD helps patients get back to basically doing everything they want to do." On the Mayo Clinic Q&A podcast, Dr. Stulak discusses technological advances in ventricular assist devices and how the therapy is underused.

Commentary by Dr. Larry Allen

Welcome to the Sterile Technique Podcast! It's the podcast about Surgical Technology. Whether you are a CST or CSFA, this podcast helps you earn CE credits and improve your surgery skills in the OR. This episode discusses the cover article of the April 2021 issue of The Surgical Technologist, which is the official journal of the Association of Surgical Technologists (AST). The article is titled, "Survival of Patients with Left Ventricular Assist Devices Undergoing Noncardiac Surgery". "Scrub in" at steriletpodcast.com and on Twitter, @SterileTPodcast (twitter.com/SterileTPodcast). This podcast is a Dybas Media production. Sound effects adapted from GarageBand and sindhu.tms at https://freesound.org/people/sindhu.tms/sounds/169065/ and licensed courtesy of https://creativecommons.org/licenses/by-nc/3.0/.

Rakesh Gopinathannair, MD, MA, talks about left ventricular assist devices, as well as how to identify and manage the challenges associated with arrhythmias. More at: www.consultant360.com/cardiology.

This week, we are getting to grips with regeneration: how does your body heal itself, and what can science do to help? Plus, in the news, the tech set to change our lives in 2019, the hidden perils of AI, and does a crossword a day really keep dementia at bay? Like this podcast? Please help us by supporting the Naked Scientists

This week, we are getting to grips with regeneration: how does your body heal itself, and what can science do to help? Plus, in the news, the tech set to change our lives in 2019, the hidden perils of AI, and does a crossword a day really keep dementia at bay? Like this podcast? Please help us by supporting the Naked Scientists

This week we review 2 works on pediatric ventricular assist devices and the most common adverse event associated with their use - specifically, infections. Dr. Scott Auerbach, medical director of the ventricular assist device program at Denver Children's Hospital and Associate Professor of Pediatrics at The University of Colorado will discuss the findings of the PEDIMACS registry data as well as share some new, hot off the presses information regarding outcomes of pediatric patients with infections who then undergo transplantation. His insights into this data set are deep and we are lucky to have him speak about this important multicenter work.

This week we review 2 works on pediatric ventricular assist devices and the most common adverse event associated with their use - specifically, infections. Dr. Scott Auerbach, medical director of the ventricular assist device program at Denver Children's Hospital and Associate Professor of Pediatrics at The University of Colorado will discuss the findings of the PEDIMACS registry data as well as share some new, hot off the presses information regarding outcomes of pediatric patients with infections who then undergo transplantation. His insights into this data set are deep and we are lucky to have him speak about this important multicenter work.

Comfortable with G-tubes, tracheostomies, and VP shunts? Good.  Get ready for the next level: Vagus Nerve Stimulators, Intrathecal Pumps, and Ventricular Assist Devices.   Details in Audio: Vagus Nerve Stimulators For intractable epilepsy; sends retrograde signal up corona radiata Also may be used in: depression, bulimia, Alzheimer, narcolepsy, addiction, and others VNS magnets Are VNS safe in MRI? Are VNS safe in everyday life? Intrathecal Pumps Used to infuse basal rate of drug, usually baclofen for spasticity, but pump may contain morphine, bupivicaine, clonidine.  Also used for severe MS, stroke, TBI, chronic pain.  Verify the medication and identify the toxidrome if symptomatic. Ventricular Assist Devices May be left ventricular assist, right ventricular assist, or biventricular assist device.   References Vagus Nerve Stimulators (VNS) Elliott RE, Rodgers SD, Bassani L et al. Vagus nerve stimulation for children with treatment-resistant epilepsy: a consecutive series of 141 cases. J Neurosurg Pediatrics. 2011; 7:491-500. Groves DA, Brown VJ. Vagal nerve stimulation: a review of its applications and potential mechanisms that mediate its clinical effects. Neuroscience and Biobehavioral Reviews. 2005; 29: 493–500. Panebianco M, Rigby A,Weston J,Marson AG. Vagus nerve stimulation for partial seizures. Cochrane Database of Systematic Reviews. 2015; 4, Art. No.: CD002896. Ruffoli R,  Giorgi FS, Pizzanelli C et al. The chemical neuroanatomy of vagus nerve stimulation. Journal of Chemical Neuroanatomy; 2011; 42: 288–296. Intrathecal Pumps Borowski A, Littleton AG, Borkhuu B et al. Complications of Intrathecal Baclofen Pump Therapy in Pediatric Patients. J Pediatr Orthop. 2010; 30:76–81. Ghosh D, Mainali G, Khera J, Luciano M.  Complications of Intrathecal Baclofen Pumps in Children: Experience from a Tertiary Care Center. Pediatr Neurosurg. 2013; 49:138–144. Yang TF, Wang JC, Chiu JW et al. Ultrasound-guided refilling of an intrathecal baclofen pump—a case report. Childs Nerv Syst. 2013; 29:347–349. Yeh RN, Nypaver MM, Deegan TJ, Ayyangar R. Baclofen Toxicity in an 8-year-old with an Intrathecal Baclofen Pump. J Emerg Med. 2004; 26(4): 163–167. Ventricular Assist Devices Blume ED, Naftel DC, Bastardi HJ et al. for the Pediatric Heart Transplant Study Investigators. Outcomes of Children Bridged to Heart Transplantation With Ventricular Assist Devices: A Multi-Institutional Study. Circulation. 2006; 113: 2313-2319. Colón JE, Laborde ME, Nossaman BD. Case Report: Left Ventricular Assist Device in a 12 Year Old Child as a Bridge to Heart Transplantation. Section of Congenital Cardiac Anesthesia, Ochsner Medical Center, New Orleans, Louisiana. 2012. Fan Y, Weng YG, Huebler M et al. Predictors of In-Hospital Mortality in Children After Long-Term Ventricular Assist Device Insertion. J Amer Coll Cardiol. 2011; 58(11):1183–90 Fraser CD,  Jaquiss RDB, Rosenthal DN et al. Prospective Trial of a Pediatric Ventricular Assist Device. N Engl J Med. 2012;367:532-41. Gazit AZ, Gandhi SK, Canter CC. Mechanical Circulatory Support of the Critically Ill Child Awaiting Heart Transplantation. Current Cardiology Reviews. 2010; 6: 46-53. VanderPluym CJ, Fynn-Thompson F, Blume ED.  Ventricular Assist Devices in Children Progress With an Orphan Device Application. Circulation. 2014;129:1530-1537. This post and podcast are dedicated to Joe Bellezzo, MD, FACEP and Zack Shinar, MD, FACEP for bringing us all up to speed.  Listen to their fantastic ED ECMO podcast here.

Margaret Parker, MD, MCCM, speaks with Robert T. Mansfield, MD

Margaret Parker, MD, MCCM, speaks with Robert T. Mansfield, MD

An article in the January issue of CGH investigated the incidence, etiology, and outcome of GI bleeding in patients with ventricular assist devices. Dr. Kuemmerle speaks to co-author Dr. John Vargo of the Cleveland Clinic.

This week’s lecture was an introduction to the Left Ventricular Assist Device given by Dr. Gautam Ramani.  In this talk Dr. Ramani discusses the fundamentals in deciding which patients should be considered for VAD placement, the different types of VADs, and finally spends the remainder of his time discussing the ...

LVADs are complicated especially when the patient starts going downhill. Zack Shinar is going to attempt to make it a bit easier.

Regenerative Medicine Today welcomes Dr. Harvey Borovetz, Mr. Stephen Winowich, and Mr. Brian Williams. Dr. Borovetz and Mr. Winowich discuss the early days of Ventricular Assist Devices, and Mr. Williams recounts his experience as one of the pioneering patients. Dr. Borovetz is a professor and chair in the Department of Bioengineering at the [...]

Host: Alfred Bove, MD Guest: Leslie Miller, MD Options for patients with advanced heart failure used to be limited to heart transplantation, but ventricular assist devices have rapidly evolved into viable treatment options for these patients. How is the newest generation of continuous-flow devices impacting the way we care for patients with advanced heart failure? Which patients are the best candidates for ventricular assist devices, or VADs, and are many patients with VADs now undergoing the procedure as destination therapy, rather than a bridge to transplant? Dr. Leslie Miller, professor and chief of the Integrated Cardiology Programs at Washington Hospital Center and Georgetown University Hospital and School of Medicine, as well as the Walters Chair in Cardiovascular Medicine at Georgetown University in Washington, DC, tells host Dr. Alfred Bove about the evolution of VADs from pulsatile pumps to continuous flow design, and the various applications for these technologies. Will these devices play a more significant role in the treatment of patients with advanced heart failure in years to come? Produced in Cooperation with

Host: Alfred Bove, MD Guest: Leslie Miller, MD Options for patients with advanced heart failure used to be limited to heart transplantation, but ventricular assist devices have rapidly evolved into viable treatment options for these patients. How is the newest generation of continuous-flow devices impacting the way we care for patients with advanced heart failure? Which patients are the best candidates for ventricular assist devices, or VADs, and are many patients with VADs now undergoing the procedure as destination therapy, rather than a bridge to transplant? Dr. Leslie Miller, professor and chief of the Integrated Cardiology Programs at Washington Hospital Center and Georgetown University Hospital and School of Medicine, as well as the Walters Chair in Cardiovascular Medicine at Georgetown University in Washington, DC, tells host Dr. Alfred Bove about the evolution of VADs from pulsatile pumps to continuous flow design, and the various applications for these technologies. Will these devices play a more significant role in the treatment of patients with advanced heart failure in years to come? Produced in Cooperation with

A ventricular assist device, also known as a VAD, is an implantable mechanical pump that helps pump blood from the lower chambers of your heart, or ventricles, to the rest of your body. Although this device can be placed in the left, right or both ventricles of your heart, it is most frequently used in the left ventricle. When placed in the left ventricle it is called a left ventricular assist device, or LVAD. A ventricular assist device is used in people who have weakened hearts or heart failure. A VAD may be implanted while the patient waits for a heart transplant or is working to get his or her heart strong enough to effectively pump blood on its own. "Patients with end-stage heart failure may be out of breath brushing their teeth or sitting in the recliner watching TV," says Dr. John Stulak, a Mayo Clinic cardiovascular surgeon. "When a patient ends up having symptoms at rest, that's the telltale sign that this is end-stage heart failure. What the LVAD does is help the left side of the heart pump and decongest the heart and get all the blood moving forward again. The VAD helps patients get back to basically doing everything they want to do." On the Mayo Clinic Q&A podcast, Dr. Stulak discusses technological advances in ventricular assist devices and how the therapy is underused. Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy